Shree Ram Proteins Board Approves Sale of Undertaking for ₹17 Crore
Shree Ram Proteins' Board approved the sale of substantially the whole undertaking for approximately ₹17 crore. Shareholder approval will be sought via postal ballot. Ms. Payal Dhamecha appointed as Scrutinizer for the postal ballot process.
The sale of 'substantially the whole of the undertaking' is a major strategic decision that will fundamentally alter the company's operations and financial structure, thus having a high impact.
The announcement details a significant corporate action (sale of undertaking) but is presented factually without immediate positive or negative indicators. The outcome is contingent on shareholder and regulatory approvals, making the sentiment neutral at this stage.
Shree Ram Proteins Limited announced that its Board of Directors, in a meeting held on August 10, 2026, approved the proposal for the sale or transfer of the whole or substantially the whole of the company's undertaking. The aggregate consideration for this transaction is approximately ₹17.00 Crore.
This approval is subject to the Members' approval through a Special Resolution via Postal Ballot and the receipt of applicable statutory and regulatory approvals. The Board also considered and approved the Postal Ballot Notice, including the calendar of events for seeking shareholder approval.
To ensure a fair and transparent process, Ms. Payal Dhamecha, a Practicing Company Secretary, has been appointed as the Scrutinizer to conduct the Postal Ballot process through remote e-voting. The meeting commenced at 12:20 P.M. and concluded at 12:50 P.M. at the company's registered office in Rajkot, Gujarat.
What to do with a filing like this
Shree Ram Proteins Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shree Ram Proteins Limited. Read the original for the full detail.